Bexitrol F Inhaler (25 mcg + 125 mcg)/puff is a combination inhalation therapy formulated with Salmeterol, a long-acting beta-2 adrenergic agonist, and Fluticasone Propionate, a potent inhaled corticosteroid. This inhaler is designed for the regular maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), particularly in patients who require effective bronchodilation along with control of airway inflammation.

Each actuation delivers a precise and consistent dose of medication directly to the lungs, ensuring targeted therapeutic action with minimal systemic exposure. Bexitrol F Inhaler helps improve lung function, reduce the frequency of respiratory symptoms, and prevent exacerbations when used regularly as prescribed. It is not intended for the relief of acute bronchospasm or sudden asthma attacks.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Long-acting beta-2 agonist (LABA) + Inhaled corticosteroid (ICS)

Indications

Bexitrol F Inhaler (25 mcg + 125 mcg)/puff is indicated for:

• Maintenance treatment of bronchial asthma in patients inadequately controlled on inhaled corticosteroids alone

• Long-term management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

• Prevention of asthma symptoms such as wheezing, shortness of breath, chest tightness, and cough

This strength is particularly suitable for patients with mild to moderate persistent asthma who require step-up therapy with a low-to-moderate dose of inhaled corticosteroid.

Pharmacology

Salmeterol is a selective long-acting beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, producing sustained bronchodilation for up to 12 hours. It helps maintain airway patency, reduces bronchospasm, and improves airflow throughout the day and night.

Fluticasone Propionate is a synthetic inhaled corticosteroid with strong anti-inflammatory effects. It works by inhibiting inflammatory mediator release, reducing airway edema, mucus secretion, and inflammatory cell activity. Regular use decreases airway hyper-responsiveness and lowers the risk of asthma exacerbations.

The combination of Salmeterol and Fluticasone Propionate provides complementary and synergistic effects, resulting in improved symptom control and better long-term disease management.

Dosage and Administration

Bexitrol F Inhaler is for inhalation use only.

• The usual recommended dose is one puff twice daily or as prescribed by a physician

• The inhaler should be used regularly at the same times each day

• Patients should rinse the mouth with water after inhalation and spit it out to reduce the risk of oral fungal infections

Proper inhaler technique is essential to achieve optimal therapeutic benefit.

Contraindications

Bexitrol F Inhaler is contraindicated in:

• Patients with known hypersensitivity to Salmeterol, Fluticasone Propionate, or any component of the formulation

• Acute asthma attacks or severe bronchospasm requiring rapid-acting bronchodilators

Side Effects

Possible side effects include:

• Throat irritation or hoarseness

• Headache

• Cough

• Oral candidiasis

• Tremor or palpitations (uncommon)

Most adverse effects are mild and reversible with correct inhaler use.

Precautions and Warnings

• Not suitable for immediate relief of acute asthma symptoms

• Use with caution in patients with cardiovascular disease, diabetes mellitus, or thyroid disorders

• Do not discontinue therapy abruptly without medical advice

• Long-term use requires periodic medical evaluation

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Pregnancy and Lactation

Bexitrol F Inhaler should be used during pregnancy and lactation only if the potential benefit justifies the potential risk and under medical supervision.

Storage Conditions

Store below 30°C in a cool, dry place. Protect from direct sunlight. Keep out of reach of children.

Conclusion

Bexitrol F Inhaler (25 mcg + 125 mcg)/puff is an effective and well-tolerated maintenance therapy for asthma and COPD. By combining sustained bronchodilation with reliable anti-inflammatory control, it helps maintain long-term symptom stability, reduces exacerbations, and supports improved respiratory health.